Berberine
16 benefits mapped to clinical evidence across supplements.
Dose per serving from products
258 products in our catalogue print how much Berberine a serving holds.
Most common: 250 mg to 500 mg, 25% of 258 products.
| Dose per serving | Products |
|---|---|
| 2.5 mg to 5 mg | 23 |
| 5 mg to 10 mg | 13 |
| 10 mg to 25 mg | 15 |
| 25 mg to 50 mg | 28 |
| 50 mg to 100 mg | 19 |
| 100 mg to 250 mg | 54 |
| 250 mg to 500 mg | 65 |
| 500 mg to 1 g | 19 |
| 1 g to 2.5 g | 21 |
| over 2.5 g | 1 |
Dose per serving from research
70 study groups in 52 studies say how much Berberine participants took a day.
These are the doses the studies gave. They are not a recommendation.
Most common: 500 mg to 1 g, 53% of 70 study groups.
| Daily dose | Study groups |
|---|---|
| 250 mg or less | 4 |
| 250 mg to 500 mg | 12 |
| 500 mg to 1 g | 37 |
| 1 g to 2.5 g | 17 |
Commonly used together
18 of 70 study groups took Berberine with something else. Shown: what 3 or more different studies gave.
What was given together, not what works together.
| Taken with | Study groups |
|---|---|
| Red Yeast Rice | 11 |
| Policosanol | 9 |
| Coenzyme Q10 | 6 |
| Folic Acid | 5 |
| Astaxanthin | 4 |
Benefit Evidence
Inflammation ↓; CRP/IL-6
Inflammation ↓; 35%→20%
Fibroinflammation ↓; ALT −4.8%
Weight loss, fat -3.5kg
Glycemia/lipids, less weight
Fat loss, waist/BMI
H. pylori/ulcer: +clearance
Diarrhoea/IBS: -30% stools
Adenoma recurrence: -11%
Liver fat, ALT −5
Lipids/insulin, liver support
ALP/cholestasis, liver enzymes
Inflammation ↓; CRP/IL-6
Inflammation ↓; 35%→20%
Fibroinflammation ↓; ALT −4.8%
Weight loss, fat -3.5kg
Glycemia/lipids, less weight
Fat loss, waist/BMI
H. pylori/ulcer: +clearance
Diarrhoea/IBS: -30% stools
Adenoma recurrence: -11%
Liver fat, ALT −5
Lipids/insulin, liver support
ALP/cholestasis, liver enzymes
Research sources
Metabolism (27)
- Berberine Ursodeoxycholate for the Treatment of Type 2 Diabetes: A Randomized Clinical Trial
PubMed ID: 40029660
Berberine‑ursodeoxycholate produced dose‑dependent improvements in HbA1c, FPG and LDL in T2D.
- [Research on therapeutic effect and hemorrheology change of berberine in new diagnosed patients with type 2 diabetes combining nonalcoholic fatty liver disease]
PubMed ID: 22308697
12‑week T2DM+NAFLD trial: berberine improved liver ultrasound, lipids and enzymes vs baseline (metabolic benefits).
- The Effects of a New Generation of Nutraceutical Compounds on Lipid Profile and Glycaemia in Subjects with Pre-hypertension
PubMed ID: 31352663
Pre‑hypertensive subjects: berberine‑containing nutraceutical reduced cholesterol and glycemia vs diet alone (multi‑ingredient but metabolic signal).
- Effectiveness and Safety of Novel Nutraceutical Formulation Added to Ezetimibe in Statin-Intolerant Hypercholesterolemic Subjects with Moderate-to-High Cardiovascular Risk
PubMed ID: 32456525
Add‑on berberine‑containing nutraceutical produced further LDL/TC lowering in statin‑intolerant patients — metabolic effect on lipids.
- Does berberine impact anthropometric, hepatic, and metabolic parameters in patients with metabolic dysfunction-associated fatty liver disease? Randomized, double-blind placebo-controlled trial
PubMed ID: 39042390
12‑week RCT in MAFLD: berberine reduced ALT, TC and trunk fat — metabolic improvements.
- HTD1801 demonstrates promising potential for histologic improvements in metabolic dysfunction-associated steatohepatitis in both a preclinical and phase 2 study
PubMed ID: 40258699
Phase‑2 berberine‑UDCA showed dose‑dependent reductions in liver fat, cT1 and ALT in presumed MASH/T2DM — strong metabolic effects.
- Long-term effects of nutraceuticals (berberine, red yeast rice, policosanol) in elderly hypercholesterolemic patients
PubMed ID: 22113535
12‑month trial in elderly statin‑intolerant patients: sustained LDL/TC lowering and improved insulin resistance (broad metabolic support).
- Nutraceutical pill containing berberine versus ezetimibe on plasma lipid pattern in hypercholesterolemic subjects and its additive effect in patients with familial hypercholesterolemia on stable cholesterol-lowering treatment
PubMed ID: 22998978
6‑month randomized study of berberine+RYY showed sizable LDL/TC reductions (multi‑component product) — supports metabolic improvement.
- Efficacy of a nutraceutical combination on lipid metabolism in patients with metabolic syndrome: a multicenter, double blind, randomized, placebo controlled trial
PubMed ID: 30885221
24‑week RCT (Armolipid Plus) in metabolic syndrome improved LDL/non‑HDL and sdLDL metrics — metabolic benefit (product contains berberine).
- Usefulness of Nutraceuticals (Armolipid Plus) Versus Ezetimibe and Combination in Statin-Intolerant Patients With Dyslipidemia With Coronary Heart Disease
PubMed ID: 26611120
Armolipid Plus in statin‑intolerant coronary patients improved LDL target attainment over 1 year (clinical metabolic outcome).
- Efficacy of berberine in patients with type 2 diabetes mellitus
PubMed ID: 18442638
Pilot RCT in T2DM showing glucose lowering and modest lipid improvements over 13 weeks.
- Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine
PubMed ID: 18397984
Placebo‑controlled RCT in T2DM with clear improvements in fasting/post‑load glucose, HbA1c and triglycerides.
- Effect of traditional Chinese medicine berberine on type 2 diabetes based on comprehensive metabonomics
PubMed ID: 20298851
Metabolomics in T2DM/dyslipidemia patients showed marked lowering of many circulating free fatty acids—supportive of metabolic effects.
- Effects of berberine on lipid profile in subjects with low cardiovascular risk
PubMed ID: 23441841
Crossover-style RCT in low‑cardiovascular‑risk subjects showing repeatable lipid improvements with berberine alone.
- Efficacy of Berberine in Patients with Non-Alcoholic Fatty Liver Disease
PubMed ID: 26252777
Large randomized multi‑center trial in NAFLD showing major reductions in hepatic fat, weight and HOMA‑IR — strong metabolic benefit.
- Short-term effects of a combined nutraceutical of insulin-sensitivity, lipid level and indexes of liver steatosis: a double-blind, randomized, cross-over clinical trial
PubMed ID: 25886384
Randomized crossover trial of a berberine‑containing nutraceutical improved LDL, TG and HOMA‑IR vs placebo.
- Lipid profiling of the therapeutic effects of berberine in patients with nonalcoholic fatty liver disease
PubMed ID: 27629750
NAFLD RCT: large decreases in hepatic fat and improvements in lipids/sphingolipids with berberine + lifestyle — meaningful metabolic effect.
- Bioimpedance analysis, metabolic effects and safety of the association Berberis aristata/Bilybum marianum: a 52-week double-blind, placebo-controlled study in obese patients with type 2 diabetes
PubMed ID: 28685558
52-week RCT in obese T2DM showing body fat, glycemic and lipid improvements with berberine + silymarin.
- Gut microbiome-related effects of berberine and probiotics on type 2 diabetes (the PREMOTE study)
PubMed ID: 33024120
Large RCT in newly diagnosed T2DM showing broad metabolic improvements (HbA1c, FPG/PPG, lipids) — strong human metabolic evidence.
- A phase 2, proof of concept, randomised controlled trial of berberine ursodeoxycholate in patients with presumed non-alcoholic steatohepatitis and type 2 diabetes
PubMed ID: 34535644
Phase 2 BUDCA in presumed NASH + diabetes: improved liver fat, glycemia and weight — robust metabolic outcomes with berberine-containing drug.
- Effectiveness and safety of Bifidobacterium and berberine in human hyperglycemia and their regulatory effect on the gut microbiota: a multi-center, double-blind, randomized, parallel-controlled study
PubMed ID: 34365978
Large RCT in newly diagnosed hyperglycemia showing modest improvements in fasting and 2‑h glucose.
- Effects of Berberine on Gut Microbiota in Patients with Mild Metabolic Disorders Induced by Olanzapine
PubMed ID: 34961418
Improved fasting glucose/insulin/HOMA‑IR and body measures in olanzapine‑treated patients.
- Combined berberine and probiotic treatment as an effective regimen for improving postprandial hyperlipidemia in type 2 diabetes patients: a double blinded placebo controlled randomized study
PubMed ID: 34923903
Combined berberine+probiotic produced large postprandial lipid and metabolic shifts in T2D.
- Efficacy and safety of HIMABERB® Berberine on glycemic control in patients with prediabetes: double-blind, placebo-controlled, and randomized pilot trial
PubMed ID: 37679692
High‑quality RCT in prediabetes with large improvements in FPG, HbA1c and HOMA‑IR.
- Pilot study on the efficacy and safety of berberine in people with metabolic syndrome and human immunodeficiency virus infection
PubMed ID: 37611246
Improved weight and insulin resistance in people with HIV/metabolic syndrome.
- Berberine phospholipid exerts a positive effect on the glycemic profile of overweight subjects with impaired fasting blood glucose (IFG): a randomized double-blind placebo-controlled clinical trial
PubMed ID: 37522683
Berberine phytosome reduced glycemia, insulin and body fat in IFG—metabolic benefits.
- Comparative Effects of Gymnema sylvestre and Berberine on Adipokines, Body Composition, and Metabolic Parameters in Obese Patients: A Randomized Study
PubMed ID: 39064727
Lowered pro‑inflammatory adipokine expression and improved body composition in obese patients.
Cholesterol (27)
- Effect of a food supplement containing berberine, monacolin K, hydroxytyrosol and coenzyme Q(10) on lipid levels: a randomized, double-blind, placebo controlled study
PubMed ID: 28579756
Double-blind RCT with berberine+monacolin K produced large LDL reductions (~26%) — substantial cholesterol benefit (combination product).
- Effects of a New Nutraceutical Formulation (Berberine, Red Yeast Rice and Chitosan) on Non-HDL Cholesterol Levels in Individuals with Dyslipidemia: Results from a Randomized, Double Blind, Placebo-Controlled Study
PubMed ID: 28704936
Double-blind RCT: berberine-containing nutraceutical reduced non-HDL (~15%) and LDL (~19%) versus placebo — clinically relevant cholesterol lowering.
- [Therapeutic Effects of Berberine Capsule on Patients with Mild Hyperlipidemia]
PubMed ID: 27491226
Randomized placebo-controlled trial in mild hyperlipidemia: berberine lowered TG/TC/LDL and raised HDL during treatment — solid lipid evidence.
- Short-term effects of a combined nutraceutical of insulin-sensitivity, lipid level and indexes of liver steatosis: a double-blind, randomized, cross-over clinical trial
PubMed ID: 25886384
Berberine‑containing nutraceutical reduced LDL and triglycerides vs placebo in overweight subjects (randomized crossover design).
- Effects of poly-bioactive compounds on lipid profile and body weight in a moderately hypercholesterolemic population with low cardiovascular disease risk: a multicenter randomized trial
PubMed ID: 25084280
Multi‑component product including berberine produced modest LDL and total cholesterol reductions vs placebo.
- Effects of berberine on lipid profile in subjects with low cardiovascular risk
PubMed ID: 23441841
Well‑designed crossover RCT showed berberine alone reduced total cholesterol, LDL and triglycerides and increased HDL in low‑risk subjects.
- Activity of isoflavones and berberine on vasomotor symptoms and lipid profile in menopausal women
PubMed ID: 22313171
Menopausal study of isoflavones+berberine showed notable decreases in total cholesterol, LDL and triglycerides (multi‑ingredient caveat).
- Berberine Ursodeoxycholate for the Treatment of Type 2 Diabetes: A Randomized Clinical Trial
PubMed ID: 40029660
Dose‑dependent LDL‑C reductions (especially at 1000 mg) in T2D berberine‑ursodeoxycholate RCT.
- Berberine phospholipid exerts a positive effect on the glycemic profile of overweight subjects with impaired fasting blood glucose (IFG): a randomized double-blind placebo-controlled clinical trial
PubMed ID: 37522683
Phytosome trial lowered total cholesterol in IFG cohort.
- Adjunctive berberine reduces antipsychotic-associated weight gain and metabolic syndrome in patients with schizophrenia: a randomized controlled trial
PubMed ID: 34931749
Adjunct trial showed significant reductions in total cholesterol and LDL over 12 weeks.
- Combined berberine and probiotic treatment as an effective regimen for improving postprandial hyperlipidemia in type 2 diabetes patients: a double blinded placebo controlled randomized study
PubMed ID: 34923903
Berberine+probiotic substantially reduced postprandial total and LDL cholesterol in newly diagnosed T2D subanalysis.
- The effect of berberine adjunctive treatment on glycolipid metabolism in patients with schizophrenia: A randomized, double-blind, placebo-controlled clinical trial
PubMed ID: 33812218
Adjunctive berberine in schizophrenia improved total cholesterol and LDL‑C over 8 weeks.
- Effect of Berberine Plus Bezafibrate Administration on the Lipid Profile of Patients with Mixed Dyslipidemia: A Pilot Clinical Trial
PubMed ID: 32397850
Small pilot: adding berberine to bezafibrate markedly improved TG and LDL, but combined treatment prevents isolation of berberine's sole effect.
- Pharmacokinetics and pharmacodynamics of HTD1801 (berberine ursodeoxycholate, BUDCA) in patients with hyperlipidemia
PubMed ID: 33183320
Berberine–UDCA salt dose-dependently lowered LDL and total cholesterol in short-term dose-ranging study.
- NUtraceutical TReatment for hYpercholesterolemia in HIV-infected patients: The NU-TRY(HIV) randomized cross-over trial
PubMed ID: 30471555
In ART-treated HIV patients, nutraceutical with berberine lowered LDL by ~19% and total cholesterol by ~14% — meaningful lipid improvements.
- Combination of simvastatin with berberine improves the lipid-lowering efficacy
PubMed ID: 18640378
Clinical trial: berberine + simvastatin produced larger LDL and triglyceride reductions than either alone — strong lipid‑lowering synergy.
- Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine
PubMed ID: 18397984
T2DM RCT included significant triglyceride reductions and favorable lipid changes.
- Comparison of Low-Dose Statin Versus Low-Dose Statin + Armolipid Plus in High-Intensity Statin-Intolerant Patients With a Previous Coronary Event and Percutaneous Coronary Intervention (ADHERENCE Trial)
PubMed ID: 28781026
Nutraceutical mix with berberine + low‑dose statin produced greater LDL/TC reductions and high LDL target attainment (multi‑ingredient).
- Usefulness of Nutraceuticals (Armolipid Plus) Versus Ezetimibe and Combination in Statin-Intolerant Patients With Dyslipidemia With Coronary Heart Disease
PubMed ID: 26611120
In statin‑intolerant coronary patients Armolipid Plus helped achieve LDL targets and was well tolerated (clinically relevant cholesterol control).
- The effect of barberry (Berberis integerrima) on lipid profile and systemic inflammation in subjects with cardiovascular risk factors: a randomized controlled trial
PubMed ID: 35255880
Dried barberry (contains berberine) improved TC/LDL and sd‑LDL modestly vs placebo.
- Efficacy of a nutraceutical combination on lipid metabolism in patients with metabolic syndrome: a multicenter, double blind, randomized, placebo controlled trial
PubMed ID: 30885221
24‑week Armolipid Plus RCT (contains berberine) reduced LDL and improved sdLDL metrics in metabolic syndrome.
- Nutraceutical approach to moderate cardiometabolic risk: results of a randomized, double-blind and crossover study with Armolipid Plus
PubMed ID: 24528686
8‑week crossover: Armolipid Plus (contains berberine) lowered TC/LDL comparable to pravastatin 10 mg (small sample).
- Nutraceutical pill containing berberine versus ezetimibe on plasma lipid pattern in hypercholesterolemic subjects and its additive effect in patients with familial hypercholesterolemia on stable cholesterol-lowering treatment
PubMed ID: 22998978
Large 6‑month RCT: berberine+RYY combination lowered LDL‑C −31.7% and TC −24.2% (substantial lipid lowering).
- Long-term effects of nutraceuticals (berberine, red yeast rice, policosanol) in elderly hypercholesterolemic patients
PubMed ID: 22113535
12‑month trial: marked LDL (−31%) and TC (−20%) reductions in elderly statin‑intolerant patients (sustained effect).
- Effects of a nutraceutical combination (berberine, red yeast rice and policosanols) on lipid levels and endothelial function randomized, double-blind, placebo-controlled study
PubMed ID: 19699071
6‑week double‑blind RCT: berberine‑containing nutraceutical lowered TC and LDL by ~1.1 mmol/L vs placebo and improved endothelial function.
- Effectiveness and Safety of Novel Nutraceutical Formulation Added to Ezetimibe in Statin-Intolerant Hypercholesterolemic Subjects with Moderate-to-High Cardiovascular Risk
PubMed ID: 32456525
Add‑on trial: berberine‑containing nutraceutical + ezetimibe produced clinically meaningful additional LDL/TC lowering vs ezetimibe alone.
- The Effects of a New Generation of Nutraceutical Compounds on Lipid Profile and Glycaemia in Subjects with Pre-hypertension
PubMed ID: 31352663
Pre‑hypertensive nutraceutical with berberine reduced TC and LDL more than diet alone (multi‑ingredient evidence).
Blood sugar (21)
- [Effects of berberine on the serum cystatin C levels and urine albumin/creatine ratio in patients with type 2 diabetes mellitus]
PubMed ID: 30541217
6-month RCT in T2DM: berberine lowered HbA1c and improved renal injury markers — supports glucose control in T2DM.
- The Effects of a New Generation of Nutraceutical Compounds on Lipid Profile and Glycaemia in Subjects with Pre-hypertension
PubMed ID: 31352663
Pre‑hypertensive nutraceutical with berberine lowered glycaemia more than diet alone over 3 months (multi‑ingredient but glucose benefit reported).
- [Research on therapeutic effect and hemorrheology change of berberine in new diagnosed patients with type 2 diabetes combining nonalcoholic fatty liver disease]
PubMed ID: 22308697
T2DM+NAFLD 12‑week trial: berberine improved glycaemia and related metabolic parameters.
- HTD1801 demonstrates promising potential for histologic improvements in metabolic dysfunction-associated steatohepatitis in both a preclinical and phase 2 study
PubMed ID: 40258699
Phase‑2 HTD1801 enrolled presumed MASH/T2DM and improved liver/metabolic outcomes; glucose effects present though not primary end‑point in abstract.
- Long-term effects of nutraceuticals (berberine, red yeast rice, policosanol) in elderly hypercholesterolemic patients
PubMed ID: 22113535
12‑month trial: berberine‑containing nutraceutical produced LDL and TC reductions and improved insulin resistance (HOMA −10%) — strong glucose/insulin signal.
- Efficacy of berberine in patients with type 2 diabetes mellitus
PubMed ID: 18442638
Pilot randomized trial in T2DM showed reductions in fasting glucose and HbA1c over 13 weeks.
- Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine
PubMed ID: 18397984
Placebo‑controlled RCT in T2DM/dyslipidemia showed substantial reductions in fasting glucose and HbA1c (−0.9% absolute).
- Effect of traditional Chinese medicine berberine on type 2 diabetes based on comprehensive metabonomics
PubMed ID: 20298851
Metabolomics showing lowered free fatty acids supports improved metabolic substrate handling relevant to glycemia.
- A clinical study on the short-term effect of berberine in comparison to metformin on the metabolic characteristics of women with polycystic ovary syndrome
PubMed ID: 22019891
PCOS RCT reduced fasting insulin and HOMA‑IR vs placebo and compared favorably with metformin for insulin‑resistance metrics.
- The use of berberine for women with polycystic ovary syndrome undergoing IVF treatment
PubMed ID: 23869585
Three months pre‑IVF in PCOS reduced fasting glucose, insulin and HOMA‑IR vs placebo — clinically meaningful glycemic benefits.
- Efficacy of Berberine in Patients with Non-Alcoholic Fatty Liver Disease
PubMed ID: 26252777
NAFLD RCT: HOMA‑IR decreased −1.06 vs −0.26 with lifestyle alone (P=0.014) — strong evidence for improved insulin sensitivity.
- Short-term effects of a combined nutraceutical of insulin-sensitivity, lipid level and indexes of liver steatosis: a double-blind, randomized, cross-over clinical trial
PubMed ID: 25886384
Berberine+chlorogenic acid nutraceutical reduced fasting insulin and HOMA‑IR vs placebo in overweight subjects.
- Bioimpedance analysis, metabolic effects and safety of the association Berberis aristata/Bilybum marianum: a 52-week double-blind, placebo-controlled study in obese patients with type 2 diabetes
PubMed ID: 28685558
Year-long obese T2DM study: berberine+silymarin improved fasting glucose and HOMA-IR — strong support for glycemic control.
- Berberine Ursodeoxycholate for the Treatment of Type 2 Diabetes: A Randomized Clinical Trial
PubMed ID: 40029660
Berberine‑ursodeoxycholate produced dose‑dependent clinically meaningful HbA1c and FPG reductions in T2D.
- Berberine phospholipid exerts a positive effect on the glycemic profile of overweight subjects with impaired fasting blood glucose (IFG): a randomized double-blind placebo-controlled clinical trial
PubMed ID: 37522683
Berberine phytosome significantly lowered fasting glycemia and insulin in IFG subjects.
- Pilot study on the efficacy and safety of berberine in people with metabolic syndrome and human immunodeficiency virus infection
PubMed ID: 37611246
Improved insulin resistance reported in HIV metabolic syndrome pilot.
- Efficacy and safety of HIMABERB® Berberine on glycemic control in patients with prediabetes: double-blind, placebo-controlled, and randomized pilot trial
PubMed ID: 37679692
Randomized double‑blind placebo‑controlled prediabetes trial with large % reductions in FPG, HbA1c and HOMA‑IR.
- Effects of Berberine on Gut Microbiota in Patients with Mild Metabolic Disorders Induced by Olanzapine
PubMed ID: 34961418
Improved FPG, fasting insulin, HOMA‑IR and HbA1c in olanzapine‑treated psychiatric patients.
- Effectiveness and safety of Bifidobacterium and berberine in human hyperglycemia and their regulatory effect on the gut microbiota: a multi-center, double-blind, randomized, parallel-controlled study
PubMed ID: 34365978
Large multicenter RCT in newly diagnosed hyperglycemia with significant FPG, 2‑hr PPG and HbA1c improvements (enhanced by probiotic).
- A phase 2, proof of concept, randomised controlled trial of berberine ursodeoxycholate in patients with presumed non-alcoholic steatohepatitis and type 2 diabetes
PubMed ID: 34535644
BUDCA reduced HbA1c (−0.6% vs +0.1%) in presumed NASH + diabetes — significant glycemic benefit with berberine-containing drug.
- Gut microbiome-related effects of berberine and probiotics on type 2 diabetes (the PREMOTE study)
PubMed ID: 33024120
Large RCT in newly diagnosed T2DM: berberine lowered HbA1c by ~1.0% and improved FPG/PPG — robust glucose-lowering evidence.
Heart health (20)
- Effects of berberine on lipid profile in subjects with low cardiovascular risk
PubMed ID: 23441841
Placebo‑controlled trial in low CVD risk subjects: berberine alone improved total cholesterol, triglycerides and LDL and increased HDL — strong cardiovascular risk marker benefit.
- Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine
PubMed ID: 18397984
RCT in T2DM/dyslipidemia showed reductions in triglycerides alongside glycemic benefits — relevant to cardiovascular risk.
- Combination of simvastatin with berberine improves the lipid-lowering efficacy
PubMed ID: 18640378
Berberine combined with simvastatin produced larger LDL and TG reductions than either alone — supports heart‑health via lipid lowering.
- Berberine ameliorates inflammation in patients with acute coronary syndrome following percutaneous coronary intervention
PubMed ID: 22220931
In ACS patients, berberine lowered inflammatory markers associated with cardiovascular risk; lipid changes were non‑significant but trending favorable.
- Effect of a food supplement containing berberine, monacolin K, hydroxytyrosol and coenzyme Q(10) on lipid levels: a randomized, double-blind, placebo controlled study
PubMed ID: 28579756
Multi-ingredient nutraceutical including berberine produced large LDL reductions (~26%) — beneficial for cardiovascular risk (combination product).
- NUtraceutical TReatment for hYpercholesterolemia in HIV-infected patients: The NU-TRY(HIV) randomized cross-over trial
PubMed ID: 30471555
Randomized cross-over in HIV patients: reductions in LDL (−19%), total cholesterol and aortic pulse wave velocity (−6%) — credible cardiovascular benefit.
- Berberine promoted myocardial protection of postoperative patients through regulating myocardial autophagy
PubMed ID: 30021340
Post-stenting RCT: berberine lowered inflammatory markers relevant to cardiac prognosis after PCI.
- Berberine alleviates oxidized low-density lipoprotein-induced macrophage activation by downregulating galectin-3 via the NF-κB and AMPK signaling pathways
PubMed ID: 30402951
Add-on berberine after PCI improved lipids and reduced galectin-3/hsCRP — supports post-ACS cardiovascular risk modulation.
- A nutraceutical combination reduces left ventricular mass in subjects with metabolic syndrome and left ventricular hypertrophy: A multicenter, randomized, double-blind, placebo-controlled trial
PubMed ID: 31371114
Multicenter RCT with Armolipid Plus (contains berberine) reduced left ventricular mass versus placebo — structural cardiac improvement (confounded by co-ingredients).
- Combined berberine and probiotic treatment as an effective regimen for improving postprandial hyperlipidemia in type 2 diabetes patients: a double blinded placebo controlled randomized study
PubMed ID: 34923903
Combined berberine+probiotic substantially reduced postprandial total and LDL cholesterol—cardiometabolic benefit.
- Preventive Effect of Berberine on Postoperative Atrial Fibrillation
PubMed ID: 36178742
Halved postoperative atrial fibrillation incidence after CABG—clear cardiac clinical benefit.
- Berberine Ursodeoxycholate for the Treatment of Type 2 Diabetes: A Randomized Clinical Trial
PubMed ID: 40029660
Dose‑dependent LDL reductions and glycemic improvement in T2D suggest cardioprotective effects.
- The Influence of Berberine on Vascular Function Parameters, Among Them VEGF, in Individuals with MAFLD: A Double-Blind, Randomized, Placebo-Controlled Trial
PubMed ID: 41305635
In MAFLD patients berberine increased VEGF and improved pulse‑wave measures and central aortic pressure.
- Effectiveness and Safety of Novel Nutraceutical Formulation Added to Ezetimibe in Statin-Intolerant Hypercholesterolemic Subjects with Moderate-to-High Cardiovascular Risk
PubMed ID: 32456525
Adding a berberine‑containing nutraceutical to ezetimibe produced larger LDL/TC reductions in statin‑intolerant patients — relevant to cardiovascular risk.
- Effects of a nutraceutical combination (berberine, red yeast rice and policosanols) on lipid levels and endothelial function randomized, double-blind, placebo-controlled study
PubMed ID: 19699071
6‑week double‑blind RCT: berberine‑containing nutraceutical significantly lowered TC/LDL and improved flow‑mediated dilation (endothelial function).
- Nutraceutical pill containing berberine versus ezetimibe on plasma lipid pattern in hypercholesterolemic subjects and its additive effect in patients with familial hypercholesterolemia on stable cholesterol-lowering treatment
PubMed ID: 22998978
6‑month RCT: berberine+red yeast rice combination reduced LDL/TC substantially vs ezetimibe — cardiovascular risk reduction potential.
- Efficacy of a nutraceutical combination on lipid metabolism in patients with metabolic syndrome: a multicenter, double blind, randomized, placebo controlled trial
PubMed ID: 30885221
24‑week Armolipid Plus RCT improved LDL/non‑HDL and sdLDL metrics in metabolic syndrome (cardio protective lipid effects).
- Usefulness of Nutraceuticals (Armolipid Plus) Versus Ezetimibe and Combination in Statin-Intolerant Patients With Dyslipidemia With Coronary Heart Disease
PubMed ID: 26611120
Armolipid Plus helped statin‑intolerant coronary patients achieve LDL goals and was well tolerated — clinically relevant heart benefit.
- Comparison of Low-Dose Statin Versus Low-Dose Statin + Armolipid Plus in High-Intensity Statin-Intolerant Patients With a Previous Coronary Event and Percutaneous Coronary Intervention (ADHERENCE Trial)
PubMed ID: 28781026
Nutraceutical mix with berberine added to low‑dose statin improved LDL/TC and target attainment in heart patients (multi‑ingredient but cardio benefit observed).
- Efficacy and safety of berberine for congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy
PubMed ID: 12860219
Randomized CHF trial: berberine improved LVEF, exercise capacity, reduced arrhythmias and mortality — strong heart benefit.
Inflammation (15)
- Protective effects of berberine on radiation-induced lung injury via intercellular adhesion molecular-1 and transforming growth factor-beta-1 in patients with lung cancer
PubMed ID: 18789680
Randomized double‑blind trial showed substantially lower incidence of radiation‑induced lung injury and reductions in sICAM‑1 and TGF‑β1.
- Berberine alleviates oxidized low-density lipoprotein-induced macrophage activation by downregulating galectin-3 via the NF-κB and AMPK signaling pathways
PubMed ID: 30402951
Add-on after PCI reduced galectin-3 and hsCRP — evidence of reduced systemic inflammation.
- Berberine promoted myocardial protection of postoperative patients through regulating myocardial autophagy
PubMed ID: 30021340
Post-PCI randomized component showed lower CRP, TNF-α and IL-6 with berberine — supports anti-inflammatory effects after cardiac intervention.
- NUtraceutical TReatment for hYpercholesterolemia in HIV-infected patients: The NU-TRY(HIV) randomized cross-over trial
PubMed ID: 30471555
Nutraceutical with berberine lowered hs-CRP (~14%) in ART-treated HIV patients — human anti-inflammatory effect.
- [Effects of berberine on serum inflammatory factors and carotid atherosclerotic plaques in patients with acute cerebral ischemic stroke]
PubMed ID: 28929697
RCT in acute ischemic stroke: berberine adjunct reduced MIF and IL-6 and improved short-term outcomes — clear anti-inflammatory signal in humans.
- Berberine ameliorates inflammation in patients with acute coronary syndrome following percutaneous coronary intervention
PubMed ID: 22220931
Add‑on trial in ACS patients demonstrated significant reductions in multiple inflammatory markers (MMP‑9, ICAM‑1, VCAM‑1, CRP, IL‑6, MCP‑1).
- Does berberine impact anthropometric, hepatic, and metabolic parameters in patients with metabolic dysfunction-associated fatty liver disease? Randomized, double-blind placebo-controlled trial
PubMed ID: 39042390
MAFLD RCT: ALT and trunk fat decreased with berberine; ALT reduction can indicate decreased hepatic inflammation.
- HTD1801 demonstrates promising potential for histologic improvements in metabolic dysfunction-associated steatohepatitis in both a preclinical and phase 2 study
PubMed ID: 40258699
HTD1801 reduced MRI‑cT1 (fibroinflammation) and ALT vs placebo — direct anti‑inflammatory signal in liver.
- The effect of barberry (Berberis integerrima) on lipid profile and systemic inflammation in subjects with cardiovascular risk factors: a randomized controlled trial
PubMed ID: 35255880
Dried barberry significantly reduced CRP vs placebo — clear systemic inflammation reduction (contains berberine).
- [The clinical study on the adjunctive effects of aqueous extract from coptis root for the treatment of chronic periodontitis]
PubMed ID: 15349657
Coptis root (berberine source) membrane decreased bleeding on probing and improved periodontal indices — local anti‑inflammatory effect.
- Berberine inhibits acute radiation intestinal syndrome in human with abdomen radiotherapy
PubMed ID: 19757213
Oral berberine reduced incidence and severity of radiation‑induced acute intestinal symptoms — clinical anti‑inflammatory/gut‑protective effect.
- Effect of Berberine Hydrochloride on the Diversity of Intestinal Flora in Parkinson's Disease Patients
PubMed ID: 35685661
Significant decreases in IL‑6, IL‑8 and TNF‑α after 3 months in Parkinson's cohort.
- Improvement of adjunctive berberine treatment on negative symptoms in patients with schizophrenia
PubMed ID: 35037116
Adjunctive reduction of multiple inflammatory cytokines in schizophrenia trial.
- Preventive Effect of Berberine on Postoperative Atrial Fibrillation
PubMed ID: 36178742
Reduced CRP, IL‑6 and LPS with clinical reduction in POAF—strong anti‑inflammatory signal.
- Effects of Berberine on Gut Microbiota in Patients with Mild Metabolic Disorders Induced by Olanzapine
PubMed ID: 34961418
Metabolic and inflammatory improvements accompanied microbiota changes in olanzapine‑treated patients.
Gut health (10)
- Gut microbiota-mediated berberine metabolism ameliorates cholestatic liver disease by suppressing 5-hydroxytryptamine production
PubMed ID: 41087029
Preclinical + small human data show microbiota‑mediated conversion of berberine with functional consequences.
- Effect of Berberine Hydrochloride on the Diversity of Intestinal Flora in Parkinson's Disease Patients
PubMed ID: 35685661
Improved gut bacterial diversity indices in Parkinson's patients after 3 months of berberine add‑on.
- Combined berberine and probiotic treatment as an effective regimen for improving postprandial hyperlipidemia in type 2 diabetes patients: a double blinded placebo controlled randomized study
PubMed ID: 34923903
Berberine+probiotic trial linked microbiome recovery (B. breve) to improved postprandial lipids and metabolomics.
- Effects of Berberine on Gut Microbiota in Patients with Mild Metabolic Disorders Induced by Olanzapine
PubMed ID: 34961418
Demonstrated compositional shifts (↓Firmicutes, ↑Bacteroides) and linked metabolic improvements.
- A randomized, multicenter and noninferiority study of amoxicillin plus berberine vs tetracycline plus furazolidone in quadruple therapy for Helicobacter pylori rescue treatment
PubMed ID: 32348007
Rescue H. pylori regimen with berberine+amoxicillin noninferior and better tolerated — supports therapeutic gut microbiota/ pathogen control.
- Gut microbiome-related effects of berberine and probiotics on type 2 diabetes (the PREMOTE study)
PubMed ID: 33024120
Study randomized arms included probiotics + berberine; changes in efficacy across arms imply microbiome interactions, though direct microbiome data limited.
- Berberine containing quadruple therapy for initial Helicobacter pylori eradication: An open-label randomized phase IV trial
PubMed ID: 28796053
Berberine-containing quadruple H. pylori therapy achieved high eradication rates and acceptable tolerability — strong gut/pathogen-balance evidence.
- A Randomized Clinical Trial of Berberine Hydrochloride in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
PubMed ID: 26400188
IBS‑D RCT showed meaningful symptom improvement (diarrhea, pain, urgency) suggesting restoration of gut function/balance.
- Berberine inhibits acute radiation intestinal syndrome in human with abdomen radiotherapy
PubMed ID: 19757213
Berberine reduced radiation‑induced acute intestinal symptoms — supports gut protective/balance effects in injured mucosa.
- [Comparison of acid and Helicobacter pylori in ulcerogenesis of duodenal ulcer disease]
PubMed ID: 8395315
Antibacterial regimens including berberine cleared H. pylori and improved gastritis — alters gut microbial/inflammatory state.
Cell health (10)
- Efficacy and safety of berberine for congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy
PubMed ID: 12860219
CHF trial improved LVEF, reduced arrhythmias and mortality — indicates beneficial effects at the cellular/cardiac tissue level.
- Berberine Ursodeoxycholate for the Treatment of Type 2 Diabetes: A Randomized Clinical Trial
PubMed ID: 40029660
Dose‑dependent improvements in glycemia, LDL and liver enzymes in T2D indicate multi‑organ cellular benefit.
- A phase 2, proof of concept, randomised controlled trial of berberine ursodeoxycholate in patients with presumed non-alcoholic steatohepatitis and type 2 diabetes
PubMed ID: 34535644
BUDCA produced reductions in liver fat, ALT and HbA1c, and weight — improvements at tissue/cellular level in liver and systemic metabolism.
- A Randomized, Dose-Finding, Proof-of-Concept Study of Berberine Ursodeoxycholate in Patients With Primary Sclerosing Cholangitis
PubMed ID: 36327436
ALP reductions in PSC suggest improvement in cholangiocyte/hepatic cellular stress biomarkers.
- HTD1801 demonstrates promising potential for histologic improvements in metabolic dysfunction-associated steatohepatitis in both a preclinical and phase 2 study
PubMed ID: 40258699
HTD1801 reduced MRI cT1 (fibroinflammation) and hepatic fat and improved ALT — suggests improved cellular liver health and reduced inflammation.
- Berberine for preventing colorectal adenoma recurrence and neoplasm occurrence: 6-Year follow-up of a randomized clinical trial
PubMed ID: 40795846
Large long‑term RCT demonstrated marked reduction in colorectal adenoma recurrence — cellular/neoplastic prevention signal.
- Protective effects of berberine on radiation-induced lung injury via intercellular adhesion molecular-1 and transforming growth factor-beta-1 in patients with lung cancer
PubMed ID: 18789680
Reduced radiation‑induced lung injury and lower TGF‑β1 and sICAM‑1 point to protection of tissue/cellular integrity during radiotherapy.
- Efficacy of Berberine in Patients with Non-Alcoholic Fatty Liver Disease
PubMed ID: 26252777
Large NAFLD trial demonstrated marked reductions in hepatic fat and improvements in HOMA‑IR and liver‑related metrics — cellular/liver health implications.
- Lipid profiling of the therapeutic effects of berberine in patients with nonalcoholic fatty liver disease
PubMed ID: 27629750
NAFLD RCT showed reductions in hepatic fat and ceramide species — changes in lipid mediators relevant to cellular health and apoptosis signaling.
- Berberine versus placebo for the prevention of recurrence of colorectal adenoma: a multicentre, double-blinded, randomised controlled study
PubMed ID: 31926918
Large multicenter RCT: berberine reduced colorectal adenoma recurrence — strong evidence of cellular/anticarcinogenic benefit in colonic mucosa.
Weight management (12)
- Comparative Effects of Gymnema sylvestre and Berberine on Adipokines, Body Composition, and Metabolic Parameters in Obese Patients: A Randomized Study
PubMed ID: 39064727
In obese adults reduced body weight, BMI, body fat and visceral fat vs comparator.
- Berberine phospholipid exerts a positive effect on the glycemic profile of overweight subjects with impaired fasting blood glucose (IFG): a randomized double-blind placebo-controlled clinical trial
PubMed ID: 37522683
Phytosome preparation reduced VAT and fat mass in overweight IFG subjects over 2 months.
- Adjunctive berberine reduces antipsychotic-associated weight gain and metabolic syndrome in patients with schizophrenia: a randomized controlled trial
PubMed ID: 34931749
Adjunct trial over 12 weeks showed modest weight/BMI reductions in antipsychotic‑treated patients.
- Effects of Berberine on Gut Microbiota in Patients with Mild Metabolic Disorders Induced by Olanzapine
PubMed ID: 34961418
Improved BMI, waist and metabolic markers over 12 weeks in olanzapine‑treated psychiatric patients.
- Berberine treatment for weight gain in patients with schizophrenia by regulating leptin rather than adiponectin
PubMed ID: 34773803
Prevented/reversed antipsychotic‑associated weight gain with ~2.5 kg group difference in 8 weeks.
- A phase 2, proof of concept, randomised controlled trial of berberine ursodeoxycholate in patients with presumed non-alcoholic steatohepatitis and type 2 diabetes
PubMed ID: 34535644
BUDCA trial: significant weight loss (−3.5 kg) with berberine–ursodeoxycholate vs placebo over 18 weeks.
- Bioimpedance analysis, metabolic effects and safety of the association Berberis aristata/Bilybum marianum: a 52-week double-blind, placebo-controlled study in obese patients with type 2 diabetes
PubMed ID: 28685558
52-week obese T2DM RCT: berberine+silymarin improved body fat and composition versus placebo — clear weight/ adiposity benefit.
- Efficacy of Berberine in Patients with Non-Alcoholic Fatty Liver Disease
PubMed ID: 26252777
Lifestyle+berberine produced significantly greater weight loss (−4.29 kg vs −1.99 kg) in NAFLD RCT — strong weight management evidence.
- The use of berberine for women with polycystic ovary syndrome undergoing IVF treatment
PubMed ID: 23869585
3‑month berberine pre‑IVF in PCOS decreased BMI and improved metabolic profile compared with placebo and performed favorably vs metformin.
- A clinical study on the short-term effect of berberine in comparison to metformin on the metabolic characteristics of women with polycystic ovary syndrome
PubMed ID: 22019891
PCOS RCT reported improved body composition (waist/WHR) compared with metformin/placebo — supportive for weight management.
- HTD1801 demonstrates promising potential for histologic improvements in metabolic dysfunction-associated steatohepatitis in both a preclinical and phase 2 study
PubMed ID: 40258699
HTD1801 reduced liver fat (PDFF) which is metabolically relevant to weight/visceral fat management.
- Does berberine impact anthropometric, hepatic, and metabolic parameters in patients with metabolic dysfunction-associated fatty liver disease? Randomized, double-blind placebo-controlled trial
PubMed ID: 39042390
MAFLD RCT: trunk fat decreased with berberine (direct body composition/weight‑related signal).
Digestive support (8)
- Efficacy and safety of triple therapy containing berberine, amoxicillin, and vonoprazan for Helicobacter pylori initial treatment: A randomized controlled trial
PubMed ID: 37469024
Berberine‑containing triple regimen achieved comparable H. pylori eradication rates in 300 patients.
- Berberine inhibits acute radiation intestinal syndrome in human with abdomen radiotherapy
PubMed ID: 19757213
Oral berberine reduced incidence/severity and delayed onset of radiation‑induced acute intestinal symptoms in abdominal/pelvic radiotherapy patients.
- [Comparison of acid and Helicobacter pylori in ulcerogenesis of duodenal ulcer disease]
PubMed ID: 8395315
Antibacterial regimens including berberine increased H. pylori clearance and improved gastritis — digestive infection benefit.
- A Randomized Clinical Trial of Berberine Hydrochloride in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
PubMed ID: 26400188
Large randomized double‑blind placebo‑controlled trial in IBS‑D showed significant reductions in diarrhea, abdominal pain and urgency with berberine hydrochloride.
- Berberine containing quadruple therapy for initial Helicobacter pylori eradication: An open-label randomized phase IV trial
PubMed ID: 28796053
Large RCT: berberine substituted for bismuth in H. pylori quadruple therapy achieved noninferior eradication — strong GI benefit for infection management.
- Berberine versus placebo for the prevention of recurrence of colorectal adenoma: a multicentre, double-blinded, randomised controlled study
PubMed ID: 31926918
Large adenoma recurrence reduction after polypectomy indicates clinically significant colonic benefit.
- A randomized, multicenter and noninferiority study of amoxicillin plus berberine vs tetracycline plus furazolidone in quadruple therapy for Helicobacter pylori rescue treatment
PubMed ID: 32348007
Large rescue H. pylori trial: berberine+amoxicillin quadruple regimen noninferior with fewer adverse events — supports GI anti-infective utility.
- Efficacy and safety of triple therapy containing berberine hydrochloride, amoxicillin, and rabeprazole in the eradication of Helicobacter pylori
PubMed ID: 36415112
Large RCT showed berberine+amoxicillin+PPI triple was noninferior for H. pylori eradication with fewer AEs—strong GI benefit.
Liver support (12)
- HTD1801 demonstrates promising potential for histologic improvements in metabolic dysfunction-associated steatohepatitis in both a preclinical and phase 2 study
PubMed ID: 40258699
Phase‑2 randomized HTD1801 (berberine‑UDCA) produced dose‑dependent, clinically meaningful liver fat and cT1 reductions and ALT improvement — strongest liver evidence.
- Gut microbiota-mediated berberine metabolism ameliorates cholestatic liver disease by suppressing 5-hydroxytryptamine production
PubMed ID: 41087029
Translational work + small human add‑on showed faster liver enzyme recovery and reduced 5‑HT in cholestasis.
- [Research on therapeutic effect and hemorrheology change of berberine in new diagnosed patients with type 2 diabetes combining nonalcoholic fatty liver disease]
PubMed ID: 22308697
12‑week T2DM+NAFLD: berberine improved liver ultrasound, ALT and other liver‑related measures vs baseline.
- Does berberine impact anthropometric, hepatic, and metabolic parameters in patients with metabolic dysfunction-associated fatty liver disease? Randomized, double-blind placebo-controlled trial
PubMed ID: 39042390
12‑week RCT in MAFLD: ALT decreased and trunk fat reduced with berberine vs placebo (liver benefit).
- The Influence of Berberine on Vascular Function Parameters, Among Them VEGF, in Individuals with MAFLD: A Double-Blind, Randomized, Placebo-Controlled Trial
PubMed ID: 41305635
In MAFLD trial, berberine produced vascular improvements and is a targeted population—some liver benefit implied.
- Berberine Ursodeoxycholate for the Treatment of Type 2 Diabetes: A Randomized Clinical Trial
PubMed ID: 40029660
Berberine‑ursodeoxycholate improved HbA1c and also improved liver tests in T2D trial (dose‑dependent).
- A Randomized, Dose-Finding, Proof-of-Concept Study of Berberine Ursodeoxycholate in Patients With Primary Sclerosing Cholangitis
PubMed ID: 36327436
Berberine‑ursodeoxycholate significantly lowered ALP in PSC patients in a phase‑2 RCT.
- A phase 2, proof of concept, randomised controlled trial of berberine ursodeoxycholate in patients with presumed non-alcoholic steatohepatitis and type 2 diabetes
PubMed ID: 34535644
BUDCA phase 2: dose-dependent reductions in liver fat (MRI-PDFF), ALT and glycemia — robust liver-targeted berberine-containing treatment evidence.
- Pharmacokinetics and pharmacodynamics of HTD1801 (berberine ursodeoxycholate, BUDCA) in patients with hyperlipidemia
PubMed ID: 33183320
Berberine–ursodeoxycholate salt reduced LDL/TC and was developed for hepatic delivery; showed liver-relevant pharmacology though primary endpoints were lipids.
- Lipid profiling of the therapeutic effects of berberine in patients with nonalcoholic fatty liver disease
PubMed ID: 27629750
NAFLD RCT: berberine + lifestyle produced large MRI-quantified reductions in hepatic fat and favorable lipid/sphingolipid changes — strong liver benefit.
- Short-term effects of a combined nutraceutical of insulin-sensitivity, lipid level and indexes of liver steatosis: a double-blind, randomized, cross-over clinical trial
PubMed ID: 25886384
Berberine‑containing nutraceutical lowered GPT and improved indices linked to liver fat vs placebo in overweight subjects.
- Efficacy of Berberine in Patients with Non-Alcoholic Fatty Liver Disease
PubMed ID: 26252777
Strong multicenter RCT in NAFLD showing 57% reduction in hepatic fat (vs 36% with lifestyle alone), plus weight and insulin resistance improvements.
Hormone balance (6)
- Comparative Effects of Gymnema sylvestre and Berberine on Adipokines, Body Composition, and Metabolic Parameters in Obese Patients: A Randomized Study
PubMed ID: 39064727
Altered adipokine gene expression (visfatin, apelin, omentin) in obese adults indicates hormone/adipokine effects.
- Berberine treatment for weight gain in patients with schizophrenia by regulating leptin rather than adiponectin
PubMed ID: 34773803
Weight/lean mass changes correlated with leptin reductions—direct evidence of hormonal modulation.
- Effect of Berberine on Cardiovascular Disease Risk Factors: A Mechanistic Randomized Controlled Trial
PubMed ID: 34444711
Double-blind RCT in men: berberine lowered total cholesterol and unexpectedly raised testosterone — direct hormonal effect observed.
- Randomized controlled trial of letrozole, berberine, or a combination for infertility in the polycystic ovary syndrome
PubMed ID: 27336209
Large RCT in PCOS: berberine alone produced lower live-birth and fecundity outcomes vs letrozole — indicates meaningful endocrine/reproductive effects (adverse for fertility).
- The use of berberine for women with polycystic ovary syndrome undergoing IVF treatment
PubMed ID: 23869585
Large randomized trial in PCOS: berberine reduced total testosterone/free androgen index, increased SHBG and improved metabolic/hormonal profile.
- A clinical study on the short-term effect of berberine in comparison to metformin on the metabolic characteristics of women with polycystic ovary syndrome
PubMed ID: 22019891
PCOS RCT reported improvements in body composition and endocrine/metabolic markers vs metformin/placebo — supports hormonal benefits.
Healthy aging (4)
- Berberine for preventing colorectal adenoma recurrence and neoplasm occurrence: 6-Year follow-up of a randomized clinical trial
PubMed ID: 40795846
Large long‑term RCT showed markedly reduced colorectal adenoma recurrence—relevant to cancer prevention/healthy aging.
- Berberine versus placebo for the prevention of recurrence of colorectal adenoma: a multicentre, double-blinded, randomised controlled study
PubMed ID: 31926918
Large trial showing reduced colorectal adenoma recurrence — clinically meaningful cancer-preventive outcome relevant to healthy aging.
- Efficacy and safety of berberine for congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy
PubMed ID: 12860219
In chronic heart failure, berberine improved LVEF, exercise capacity and reduced mortality — outcomes that can support healthier aging (cardiac survival signal).
- Long-term effects of nutraceuticals (berberine, red yeast rice, policosanol) in elderly hypercholesterolemic patients
PubMed ID: 22113535
12‑month lipid and insulin improvements in elderly statin‑intolerant patients — supports metabolic health in older adults.
Immune support (5)
- [Comparison of acid and Helicobacter pylori in ulcerogenesis of duodenal ulcer disease]
PubMed ID: 8395315
Antibacterial regimens including berberine increased H. pylori clearance and improved gastritis vs ranitidine (moderate, multi‑drug regimens).
- Effect of Berberine Hydrochloride on the Diversity of Intestinal Flora in Parkinson's Disease Patients
PubMed ID: 35685661
Lowered IL‑6/IL‑8/TNF‑α in Parkinson's patients—systemic anti‑inflammatory signal.
- Preventive Effect of Berberine on Postoperative Atrial Fibrillation
PubMed ID: 36178742
Reduced postoperative inflammation markers (CRP, IL‑6, LPS) alongside clinical benefit.
- Protective effects of berberine on radiation-induced lung injury via intercellular adhesion molecular-1 and transforming growth factor-beta-1 in patients with lung cancer
PubMed ID: 18789680
Reductions in inflammatory/fibrotic markers and lower incidence of radiation lung injury suggest immune-modulatory/anti‑inflammatory effects (clinical RCT).
- Treatment of chloroquine-resistant malaria using pyrimethamine in combination with berberine, tetracycline or cotrimoxazole
PubMed ID: 9337003
Pyrimethamine+berberine produced higher parasite clearance in chloroquine‑resistant malaria — direct antimicrobial/immunologic benefit.
Skin health (2)
- Effects of berberine gelatin on recurrent aphthous stomatitis: a randomized, placebo-controlled, double-blind trial in a Chinese cohort
PubMed ID: 23246229
Double‑blind RCT: topical berberine gelatin reduced pain, size and inflammation of minor aphthous ulcers vs placebo — clear mucocutaneous benefit.
- Efficiency of a biodegradable gel containing hyaluronic acid and berberine hydrochloride in endoscopic sinus surgery (ESS): A prospective comparative study
PubMed ID: 35210111
Topical hyaluronic acid + berberine gel improved early endoscopic healing scores and postoperative symptoms after sinus surgery (wound/healing relevance).
Energy & Fatigue (1)
- Efficacy and safety of berberine for congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy
PubMed ID: 12860219
CHF trial reported increased exercise capacity (6‑minute walk) with berberine — may translate to improved energy/exertional tolerance.
Blood pressure (1)
- The Influence of Berberine on Vascular Function Parameters, Among Them VEGF, in Individuals with MAFLD: A Double-Blind, Randomized, Placebo-Controlled Trial
PubMed ID: 41305635
Berberine reduced central aortic systolic pressure (PWA‑SP) and improved PWV after adjustment in MAFLD RCT.
Forms of Berberine
The form a label may print instead of Berberine. Each is a different substance with its own identifier, and none of them has research of its own — the studies are the ones on this page.
Similar by evidence
Supplements the same benefits carry qualifying findings for — a fact about the evidence graph, not a recommendation to swap.
Products with Berberine
Search all516 products whose verified label declares Berberine — not every bottle that mentions it in a title.
Being studied right now
Recruiting clinical trials registered on ClinicalTrials.gov. A trial in progress has no result yet — this is what the field is asking, not what it found.